There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours. Esketamine, the S-enantiomer of ketamine, has emerged as a novel therapeutic option. Esketamine, initially introduced as an add-on therapy, has more recently also received recognition for use as a standalone treatment.
Esketamine nasal spray was the first glutamate-modulating antidepressant to enter clinical practice and was recently approved as the first and only monotherapy for adults with TRD. Administered at 56 mg or 84 mg, esketamine offers a rapid onset of action. Moment of Clarity has released a detailed educational resource outlining the clinical steps involved in Spravato treatment for recovery and how this FDA-approved therapy is integrated into structured ... Esketamine was introduced for medical use as an anesthetic in Germany in 1997, and was subsequently marketed in other countries.
esketamine therapy, [5][22] In addition to its anesthetic effects, the medication showed properties of being a rapid-acting antidepressant, and was subsequently investigated for use as such. [59][60] Esketamine received a breakthrough ... What is esketamine? Esketamine is a nasal spray that is used together with an oral (taken by mouth) antidepressant to treat adults with depression that is resistant to other treatments. Esketamine is an intranasal antidepressant medication that works in the brain.
esketamine therapy, It is FDA approved for the treatment of major depressive disorder (MDD) with suicidal thoughts and behavior as well as treatment-resistant depression (TRD) in conjunction with an oral antidepressant. Esketamine nasal spray is used with or without an antidepressant taken by mouth, to treat depression in patients who have previously received at least 2 antidepressant treatments that did not work well (treatment-resistant depression).
